Literature DB >> 1489941

Bioavailability of lithium from lithium citrate syrup versus conventional lithium carbonate tablets.

P J Guelen1, T J Janssen, T C De Witte, T B Vree, K Benson.   

Abstract

The bioavailability of lithium citrate syrup was compared with that of regular lithium carbonate tablets in 18 healthy male human volunteers. Blood samples were collected up to 48 h after dosing. Lithium serum concentrations were determined by means of AAS. The absorption rate following oral administration of the syrup was greater (tmax 0.8 h) than following administration of regular tablets (tmax 1.4 h). Maximum lithium serum concentrations, however, were only about 10 per cent higher after syrup dosing and serum concentrations resulting from syrup and tablets were almost superimposable from 2 h after dosing. The terminal half-life of lithium was found to be 22 h after syrup as well as after tablet dosing. No side-effects were observed during the study. The bioavailability of lithium from syrup relative to tablets was found to be bioequivalent with respect to the maximum lithium serum concentration and the extent of drug absorption (AUC).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1489941     DOI: 10.1002/bdd.2510130704

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  2 in total

1.  Lithium for acute mania.

Authors:  Rebecca F McKnight; Saïk J G N de La Motte de Broöns de Vauvert; Edward Chesney; Ben H Amit; John Geddes; Andrea Cipriani
Journal:  Cochrane Database Syst Rev       Date:  2019-06-01

2.  Lithium for Fracture Treatment (LiFT): a double-blind randomised control trial protocol.

Authors:  Diane Nam; Phumeena Balasuberamaniam; Katrine Milner; Monica Kunz; Kathak Vachhani; Alex Kiss; Cari Whyne
Journal:  BMJ Open       Date:  2020-01-07       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.